ADMS Technology

The development of small molecule innovative drugs has entered a new era of the targeted therapy. The affinity based high-throughput screening platform, developed independently by Keythera Biopharmaceuticals, focuses on the disease areas with unmet medical needs. This technology platform enabled the discovery of the innovative hits, and then developed the true new drugs successfully. Traditional high-throughput screening technologies primarily rely on fluorescence detection methods for functional screening. However, such methods have several limitations, such as low sensitivity, high false negative rates, high compound and target requirements, difficulty in screening multi-component mixtures, and operational complexity. Although DNA encoded library screening technology greatly improves the sensitivity and throughput of high-throughput screening, the diversity of its compound libraries is significantly limited, and the possibility of discovering new drug structural spaces is much lower compared to traditional methods. In contrast, the ADMS screening technology can effectively overcome the aforementioned limitations of traditional high-throughput drug screening technologies and ultra-high throughput DNA encoded screening technology. It combines the important advantages of both mainstream methods and offers better solutions.